IntegenX® has brought together a management team of strategic leaders selected for extensive scientific and engineering experience, complemented by strong expertise in product commercialization for the life sciences.
Robert A. Schueren
Chief Executive Officer
Bob has nearly 30 years of commercial and operational experience, and holding leadership positions in life science and diagnostic companies for more than two decades. Most recently, he was Vice President and General Manager, Genomics for Agilent Technologies. Prior to joining Agilent in 2010, he was the Global Head of Clinical Biomarkers and Operations, and Deputy Global Head of Molecular Medicine Labs for Genentech, Inc., a company he joined in 2006. While at Genentech, Bob held increasingly responsible positions including Senior Director, Development Sciences and Director Companion Diagnostics. Prior to Genentech, he was the Executive Vice President and Chief Operating Officer of Arcturus Bioscience from 2003 to 2006. From 1997 to 2002, Bob held senior leadership positions with Accumetrics and previously held commercial positions with Biosite Diagnostics, Gen-Probe and Abbott Diagnostics. Bob holds a BS in Pharmacy from Temple University, and serves as a member of the board of directors for IntegenX.
David V. Smith
Chief Operating Officer
David V. Smith joined IntegenX in May 2012. He has over 30 years of financial and operational management experience, and has held leadership positions in the biotechnology industry for more than two decades. Prior to IntegenX, he was Executive Vice President and Chief Financial Officer of Thoratec Corporation. Prior to joining Thoratec in 2006, Mr. Smith served as Vice President and Chief Financial Officer of Chiron Corporation, which he joined in 1999, and where he held a number of increasingly responsible positions including Vice President, Principal Accounting Officer and Controller, and Vice President of Finance. Mr. Smith served as the Vice President of Finance and Chief Financial Officer at Anergen Incorporated from 1997 to 1999. From 1988 to 1997, Mr. Smith served in various financial management positions with Genentech, Inc., both in the United States and Europe. He previously held finance positions at Syntex Corporation and IBM Corporation.
Mr. Smith is currently chair of the Audit Committee and a Director of OncoGenex Pharmaceuticals, Inc. and was previously chair of the Audit Committee and a Director of Perlegen Sciences, Inc. He holds a B.A. in Economics and History from Willamette University and an M.B.A. specializing in finance from Golden Gate University.
Stevan Jovanovich, Ph.D.
Co-Founder of IntegenX
Chief Technology Officer
Dr. Stevan Jovanovich co-founded IntegenX (then named Microchip Biotechnologies) in 2003 to better optimize sample preparation for the life sciences. At IntegenX he has been the Principal Investigator on over $10M of grants and contracts focused on DNA sequencing, biodefense, and forensics. He leads a growing team of talented professionals dedicated to commercializing the technologies.
Dr. Jovanovich is an internationally recognized expert in microfluidics and an experienced global commercial leader. Prior to co-founding IntegenX, Dr. Jovanovich was Vice President of Global Research at Amersham Biosciences (now part of GE Healthcare) where he led a team of 120 scientists and engineers and drove multiple business projects across six international sites. Previous positions include Science Director at Amersham Biosciences, Manager of Advanced Research at Molecular Dynamics, Staff Scientist at Lawrence Berkeley National Laboratory, Director of Microbiology at AbTox, and founder of Molecular Solutions.
Dr. Jovanovich has proven expertise in microbiology, molecular genetics, microbial physiology, object-oriented programming, robotics, genomics, systems biology, and instrument and systems development. He has authored over 20 scientific publications and is an inventor on more than 20 US patents. He holds Bachelor of Science degrees in Physics and Life Sciences from MIT, and a Ph.D. in Microbiology from the University of California at Davis. Currently, he serves as a member of the board of directors for IntegenX.
Executive Vice President, Operations
Ms. Frost joined IntegenX in May 2010 to develop the company’s operational organization and infrastructure. Prior to IntegenX, Ms. Frost earned positions of increasing operational responsibility over the course of 20 years of service at Applied Biosystems, now part of Life Technologies. As Vice President of Global Nucleotide Operations and as Vice President of Customer Services and Distribution at Applied Biosystems, Ms. Frost built and led global supply chain, product and process development, manufacturing, quality assurance, distribution, and customer service organizations for life science and biotech laboratory products. She has also consulted extensively to the life science, nanotechnology, healthcare, and viniculture industries, providing her clients with operational assessments and strategies for infrastructure development and scalability.
Ms. Frost studied Business Administration at San Francisco State University.
Executive Vice President, Commercial Operations
Tom Olenic joined IntegenX in June 2012. He has over 25 years of commercial and operational experience and has held many leadership roles in the life science industry. Prior to joining IntegenX, he was SVP and General Manager of Molecular Devices. Mr. Olenic has also held senior management roles at MDS, Danaher and FreeSlate. He has previously held commercial roles at Bios, Millipore and PerSeptive Biosystems.
Tom holds a B.S. in Biology from the University of South Florida.
Executive Vice President, Product Development
David joined IntegenX in March 2013. David has over 20 years experience in the diagnostics and life science tools industries. Previously, David was Vice President of Product Development at Affymetrix, where he led introduction of next-generation instrument platforms, genome and transcriptome analysis products. Prior to Affymetrix, David served as Vice President, R&D and Operations at Guava Technologies (acquired by EMD Millipore Corporation). At Guava, David commercialized research and clinical flow cytometry instrument platforms and applications and expansion of Guava’s international service and support organization. King holds a Ph.D. from Stanford University and a B.Sc.(Hons) from University of New South Wales, Australia. In addition, King is an inventor on 31 granted US patents in areas including nucleic acid & protein detection, cellular analysis instrumentation and applications, point-of-care medical diagnostics, DNA microarrays, MEMS-based optical telecommunications and lasers & optics.